Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells

Journal of Pathology

Volumn 231, Issue 4, 2013, Pages 495-504

  Shimada, Keiji ^a   Anai, Satoshi ^a   Fujii, Tomomi ^a   Tanaka, Nobumichi ^a   Fujimoto, Kiyohide ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

holoclone; ROS; syndecan 1; tumour initiating cells

Indexed keywords

CD133 ANTIGEN; DOCETAXEL; HERMES ANTIGEN; HYDROGEN PEROXIDE; OGT 2115; OXYGEN RADICAL; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RNA; SYNDECAN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; EARLY INTERVENTION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE CELL ANALYSIS; UPREGULATION;

HOLOCLONE; ROS; SYNDECAN-1; TUMOUR-INITIATING CELLS;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENETIC THERAPY; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, SCID; MICE, TRANSGENIC; NADPH OXIDASE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RECURRENCE; SYNDECAN-1; TAXOIDS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84887542459     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4271     Document Type: Article

References (38)

1. Shimada K, Nakamura M, Ishida E, et al., Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. Histol Histopathol 2006; 21: 415-422.
2. Konishi N, Shimada K, Ishida E, et al., Molecular pathology of prostate cancer. Pathol Int 2005; 55: 531-539.
3. Frame FM, Maitland NJ,. Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv Exp Med Biol 2011; 720: 105-118.
4. Marcinkiewicz K, Scotland KB, Boorjian SA, et al., The androgen receptor and stem cell pathways in prostate and bladder cancers [review]. Int J Oncol 2012; 40: 5-12.
5. Konishi N, Shimada K, Nakamura M, et al., Function of JunB in transient amplifying cell senescence and progression of human prostate cancer. Clin Cancer Res 2008; 14: 4408-4416.
6. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-1708.
7. Bernfield M, Gotte M, Park PW, et al., Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777.
8. Dhodapkar MV, Abe E, Theus A, et al., Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998; 91: 2679-2688.
9. Wijdenes J, Vooijs WC, Clement C, et al., A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94 (2): 318-323.
10. Mahtouk K, Cremer FW, Reme T, et al., Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 2006; 25: 7180-7191.
11. Yang Y, MacLeod V, Dai Y, et al., The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007; 110: 2041-2048.
12. Shimada K, Nakamura M, De Velasco MA, et al., Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci 2009; 100: 1248-1254.
13. Lendorf ME, Manon-Jensen T, Kronqvist P, et al., Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem 2011; 59 (6): 615-629.
14. Kim YJ, Go H, Wu HG, et al., Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck 2011; 33: 1458-1466.
15. Hasengaowa, Kodama J, Kusumoto T, et al., Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann Oncol 2005; 16: 1109-1115.
16. Shimada K, Nakamura M, De Velasco MA, et al., Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci 2010; 101: 155-160.
17. Tan L, Sui X, Deng H, et al., Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. PLoS One 2011; 6: e23383.
18. Fujii T, Shimada K, Anai S, et al., ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression. Cancer Sci 2013; 104: 321-327.
19. Shimada K, Fujii T, Tsujikawa K, et al., ALKBH3 contributes to survival and angiogenesis of human urothelial carcinoma cells through NADPH oxidase and tweak/Fn14/VEGF signals. Clin Cancer Res 2012; 18: 5247-5255.
20. Shimada K, Fujii T, Anai S, et al., ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder. BMC Urol 2011; 11: 22.
21. Shimada K, Nakamura M, Ishida E, et al., c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. Am J Pathol 2007; 171: 1003-1012.
22. Tasaki M, Shimada K, Kimura H, et al., ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer. Br J Cancer 2011; 104: 700-706.
23. Shimada K, Nakamura M, Anai S, et al., A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer Res 2009; 69: 3157-3164.
24. Greenberg NM, DeMayo F, Finegold MJ, et al., Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-3443.
25. Riddle ND, Gorden L, Rojiani MV, et al., CD44 and p53 immunoexpression patterns in NF1 neoplasms-indicators of malignancy and infiltration. Int J Clin Exp Pathol 2010; 3: 515-521.
26. Makarov DV, Trock BJ, Humphreys EB, et al., Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-1101.
27. Stephenson AJ, Scardino PT, Eastham JA, et al., Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715-717.
28. Netto GJ,. Molecular diagnostics in urologic malignancies: a work in progress. Arch Pathol Lab Med 2011; 135: 610-621.
29. Sakurai T, Kudo M, Umemura A, et al., p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res 2013; 73: 215-224.
30. Jamal M, Rath BH, Williams ES, et al., Microenvironmental regulation of glioblastoma radioresponse. Clin Cancer Res 2010; 16 (24): 6049-6059.
31. Lagadinou ED, Sach A, Callahan K, et al., BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013; 12: 329-341.
32. Sun Y, St Clair DK, Xu Y, et al., A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res 2010; 70: 2880-2890.
33. Srivastava S, Krishna S,. Cancer stem cells: an approach to identify newer therapeutic targets. J Stem Cells 2009; 4: 123-131.
34. Brimo F, Partin AW, Epstein JI,. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology 2010; 76: 1206-1209.
35. Aydin H, Tsuzuki T, Hernandez D, et al., Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology 2004; 64: 551-555.
36. Tan PH, Cheng L, Srigley JR, et al., International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol 2011; 24: 48-57.
37. Elangovan S, Ramachandran S, Venkatesan N, et al., SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor-α in breast cancer. Cancer Res 2011; 71: 6654-6664.
38. Zhang J, Nuebel E, Daley GQ, et al., Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 2012; 11: 589-595.